Stock Analiz

Abeona Therapeutics Inc. ABEO

Biotechnology: Pharmaceutical Preparations · data as of November 13, 2026

$2.42Market cap $138M
Open the interactive analysis →

Abeona Therapeutics Inc. (ABEO) is a healthcare company listed in the US with a market value of about $138M. In the twelve months to September 30, 2026 it had revenue of $39M and net income of -$63M, a net margin of -160.3%.

Its overall Stock Analiz score is 0.8 out of 5 (weak). The strongest part is financial health (2/5); the weakest is value (0/5).

Key numbers: a 5-year average ROIC of -112%.

About Abeona Therapeutics

Abeona Therapeutics is listed in the US and classified in biotechnology: pharmaceutical preparations. Revenue went from $925000 in 2014 to $4M in 2023, growth of about 15.9% a year. It was profitable in 1 of the last 10 years in our data. Its share count rose by 741% over three years (dilution for shareholders).

Score: 0.8 / 5

Value0/5
Future growth1/5
Track record1/5
Financial health2/5
Shareholder returns0/5

Checks passed

  • Strong R&D investment or growth above 20%
  • ROE above 15%
  • More cash than debt, or low debt to equity
  • Liabilities below 60% of assets

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • Profit margin improving

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S3.5
P/B1.1
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield-48.0%
Shareholder yield0.0%
Intrinsic value vs. price—

Growth and quality

Revenue growth (1 yr)—
Revenue growth (5 yrs, per year)—
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-2395.6%
ROIC (5-yr avg.)-112.5%
Profitable years (of last 10)1
Years paying a dividend—

Financials, last 10 years

Fiscal yearTTM2025202420232022202120202019201820172016
Revenue$39M——$4M$1M$3M$10M—$3M$837000$2M
Net income-$63M$71M-$64M-$54M-$40M-$85M-$84M-$76M-$57M-$27M-$22M
Free cash flow-$66M-$84M-$58M-$37M-$44M-$70M-$36M-$69M-$48M-$24M-$14M
EPS (diluted)$-1.07$1.01$-1.55$-2.53$-5.53$-0.86$-0.91$-1.51$-1.19$-0.66$-0.64
Net margin-160.3%——-1548.2%-2807.4%-2831.2%-842.3%—-1890.3%-3263.9%-931.6%
ROIC—-48.5%-75.6%-184.1%-117.0%-137.2%-58.7%-32.7%-34.3%-12.9%-19.0%

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

Frequently asked questions

Does Abeona Therapeutics pay a dividend?

Not currently.

Is Abeona Therapeutics a good stock to buy?

We do not give buy or sell advice. Abeona Therapeutics scores 0.8 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.